{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:08:57Z","timestamp":1789765737828,"version":"4.0.1"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Iron overload cardiomyopathy (IOC) is a major co-morbidity of genetic hemochromatosis and secondary iron overload with limited therapeutic options. We aim to investigate mechanisms of rescue action of amlodipine in the murine model of iron overload, characterize changes in human cardiac tissue due to IOC, and compare them to the changes in the animal model of IOC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and results<\/jats:title><jats:p>As an animal model, we used male hemojuvelin knockout (HJVKO) mice, which lacked hemojuvelin (a co-receptor protein for hepcidin expression). The mice were fed a high-iron diet from 4 weeks to 1 year of age. As a rescue, iron-fed mice received the Ca<jats:sup>2+<\/jats:sup> channel blocker, amlodipine, from 9 to 12 months. Iron overload resulted in systolic and diastolic dysfunctions and changes in the cardiac tissue similar to the changes in the explanted human heart with IOC. An IOC patient (\u03b2-thalassemia) with left-ventricular ejection fraction (LVEF) 25% underwent heart transplantation. The murine model and the explanted heart showed intra-myocyte iron deposition, fibrosis, hypertrophy, oxidative stress, remodeling of Ca<jats:sup>2+<\/jats:sup> cycling proteins, and metabolic kinases typical of heart failure. Single-myocyte contractility and Ca<jats:sup>2+<\/jats:sup> release were diminished in the murine model. The amlodipine-treated group exhibited normalization of cellular function and reversed fibrosis, hypertrophy, oxidative stress, and metabolic remodeling. We also report a clinical case of primary hemochromatosis successfully treated with amlodipine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The aged HJVKO murine model on the iron-rich diet reproduced many features of the human case of IOC. The use of amlodipine in the murine model and clinical case reversed IOC remodeling, demonstrating that amlodipine is effective adjuvant therapy for IOC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2023.1129349","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T04:28:44Z","timestamp":1682051324000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Amlodipine rescues advanced iron overload cardiomyopathy in hemojuvelin knockout murine model: Clinical implications"],"prefix":"10.3389","volume":"10","author":[{"given":"Pavel","family":"Zhabyeyev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandu","family":"Sadasivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumya","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin Y.","family":"Oudit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.cmet.2013.02.004","article-title":"Iron and copper in mitochondrial diseases","volume":"17","author":"Xu","year":"2013","journal-title":"Cell Metab"},{"key":"B2","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0092-8674(04)00343-5","article-title":"Balancing acts: molecular control of mammalian iron metabolism","volume":"117","author":"Hentze","year":"2004","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehw386","article-title":"Unravelling the molecular basis for cardiac iron metabolism and deficiency in heart failure","volume":"38","author":"Zhabyeyev","year":"2017","journal-title":"Eur Heart J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cjca.2017.04.013","article-title":"Hemochromatosis protein (HFE) knockout mice as a novel model of hemochromatosis: implications for study and management of iron-overload cardiomyopathy","volume":"33","author":"Zhabyeyev","year":"2017","journal-title":"Can J Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/S0140-6736(15)01315-X","article-title":"Haemochromatosis","volume":"388","author":"Powell","year":"2016","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMra2119758","article-title":"Hemochromatosis","volume":"387","author":"Olynyk","year":"2022","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.hoc.2014.04.006","article-title":"Diagnostic evaluation of hereditary hemochromatosis (HFE and non-HFE)","volume":"28","author":"Bardou-Jacquet","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"key":"B8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.gene.2015.10.009","article-title":"HFE gene: structure, function, mutations, and associated iron abnormalities","volume":"574","author":"Barton","year":"2015","journal-title":"Gene"},{"key":"B9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/ng1053","article-title":"Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis","volume":"33","author":"Roetto","year":"2003","journal-title":"Nat Genet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/ejhf.708","article-title":"Heart failure in haemoglobinopathies: pathophysiology, clinical phenotypes, and management","volume":"19","author":"Farmakis","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"B11","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40265-016-0569-0","article-title":"Iatrogenic iron overload in dialysis patients at the beginning of the 21st century","volume":"76","author":"Rostoker","year":"2016","journal-title":"Drugs"},{"key":"B12","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1161\/CIR.0b013e31829b2be6","article-title":"Cardiovascular function and treatment in beta-thalassemia major: a consensus statement from the American heart association","volume":"128","author":"Pennell","year":"2013","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ejphar.2015.08.017","article-title":"Current and future treatment strategies for iron overload cardiomyopathy","volume":"765","author":"Wongjaikam","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1527-3466.2002.tb00084.x","article-title":"Efonidipine hydrochloride: a dual blocker of L- and T-type Ca2+ channels","volume":"20","author":"Tanaka","year":"2002","journal-title":"Cardiovasc Drug Rev"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/nm920","article-title":"L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy","volume":"9","author":"Oudit","year":"2003","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1113\/EP085517","article-title":"Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice","volume":"101","author":"Kumfu","year":"2016","journal-title":"Exp Physiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.amjmed.2013.05.002","article-title":"Amlodipine reduces cardiac iron overload in patients with thalassemia major: a pilot trial","volume":"126","author":"Fernandes","year":"2013","journal-title":"Am J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e005360","DOI":"10.1136\/bmjopen-2014-005360","article-title":"Effect of L-type calcium channel blocker (amlodipine) on myocardial iron deposition in patients with thalassaemia with moderate-to-severe myocardial iron deposition: protocol for a randomised, controlled trial","volume":"4","author":"Shakoor","year":"2014","journal-title":"BMJ Open"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1182\/blood-2016-06-721183","article-title":"A randomized trial of amlodipine in addition to standard chelation therapy in patients with thalassemia major","volume":"128","author":"Fernandes","year":"2016","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"B21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1006\/jmcc.1998.0867","article-title":"Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine","volume":"31","author":"Mason","year":"1999","journal-title":"J Mol Cell Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s12010-019-03009-x","article-title":"Anti-diabetic properties of calcium channel blockers: inhibition effects on aldose reductase enzyme activity","volume":"189","author":"Turkes","year":"2019","journal-title":"Appl Biochem Biotechnol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1080\/07391102.2020.1736631","article-title":"Calcium channel blockers: molecular docking and inhibition studies on carbonic anhydrase I and II isoenzymes","volume":"39","author":"Turkes","year":"2021","journal-title":"J Biomol Struct Dyn"},{"key":"B24","first-page":"467","article-title":"Comparative bioavailability cf two amlodipine formulation in healthy volunteers","volume":"57","author":"Setiawati","year":"2007","journal-title":"Arzneimittelforschung"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e23228","DOI":"10.1002\/jcla.23228","article-title":"Evaluation of pharmacokinetics and safety with bioequivalence of amlodipine in healthy Chinese volunteers: bioequivalence study findings","volume":"34","author":"Wang","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"B26","doi-asserted-by":"publisher","first-page":"18132","DOI":"10.1038\/srep18132","article-title":"Iron-overload injury and cardiomyopathy in acquired and genetic models is attenuated by resveratrol therapy","volume":"5","author":"Das","year":"2015","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"BSR20171302","DOI":"10.1042\/BSR20171302","article-title":"Advanced iron-overload cardiomyopathy in a genetic murine model is rescued by resveratrol therapy","volume":"38","author":"Das","year":"2018","journal-title":"Biosci Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1172\/JCI25049","article-title":"A mouse model of juvenile hemochromatosis","volume":"115","author":"Huang","year":"2005","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1161\/CIRCRESAHA.111.300299","article-title":"Loss of p47phox subunit enhances susceptibility to biomechanical stress and heart failure because of dysregulation of cortactin and actin filaments","volume":"112","author":"Patel","year":"2013","journal-title":"Circ Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/cvr\/cvv016","article-title":"PI3K\u03b1 is essential for the recovery from cre\/tamoxifen cardiotoxicity and in myocardial insulin signalling but is not required for normal myocardial contractility in the adult heart","volume":"105","author":"McLean","year":"2015","journal-title":"Cardiovasc Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.yjmcc.2019.05.008","article-title":"Inhibition of PI3Kinase-alpha is pro-arrhythmic and associated with enhanced late Na(+) current, contractility, and Ca(2+) release in murine hearts","volume":"132","author":"Zhabyeyev","year":"2019","journal-title":"J Mol Cell Cardiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1042\/CS20130787","article-title":"Loss of NOX2 (gp91phox) prevents oxidative stress and progression to advanced heart failure","volume":"127","author":"Parajuli","year":"2014","journal-title":"Clin Sci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/liv.12893","article-title":"Resveratrol mediates therapeutic hepatic effects in acquired and genetic murine models of iron-overload","volume":"36","author":"Das","year":"2016","journal-title":"Liver Int"},{"key":"B34","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1186\/s12859-018-2486-6","article-title":"iDEP: an integrated web application for differential expression and pathway analysis of RNA-seq data","volume":"19","author":"Ge","year":"2018","journal-title":"BMC Bioinform"},{"key":"B35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41569-022-00735-4","article-title":"The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease","volume":"20","author":"Fang","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1046377","DOI":"10.3389\/fcvm.2022.1046377","article-title":"Mapping current research and identifying hotspots of ferroptosis in cardiovascular diseases","volume":"9","author":"Teng","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e022853","DOI":"10.1161\/JAHA.121.022853","article-title":"Myocardial iron deficiency and mitochondrial dysfunction in advanced heart failure in humans","volume":"11","author":"Zhang","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e003456","DOI":"10.1161\/JAHA.116.003456","article-title":"Females are protected from iron-overload cardiomyopathy independent of iron metabolism: key role of oxidative stress","volume":"6","author":"Das","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"B39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa073286","article-title":"Iron-overload-related disease in HFE hereditary hemochromatosis","volume":"358","author":"Allen","year":"2008","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.cardfail.2010.05.009","article-title":"Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment","volume":"16","author":"Murphy","year":"2010","journal-title":"J Card Fail"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.jacc.2010.03.083","article-title":"Iron overload cardiomyopathy: better understanding of an increasing disorder","volume":"56","author":"Gujja","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1159\/000430173","article-title":"Thrombopoietin protects cardiomyocytes from iron-overload induced oxidative stress and mitochondrial injury","volume":"36","author":"Chan","year":"2015","journal-title":"Cell Physiol Biochem"},{"key":"B44","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/1099800403261350","article-title":"Ebselen decreases oxygen free radical production and iron concentrations in the hearts of chronically iron-overloaded mice","volume":"6","author":"Davis","year":"2004","journal-title":"Biol Res Nurs"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJM199610103351504","article-title":"Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective randomized amlodipine survival evaluation study group","volume":"335","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jchf.2013.04.004","article-title":"Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2)","volume":"1","author":"Packer","year":"2013","journal-title":"JACC Heart Fail"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1129349\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T04:28:47Z","timestamp":1682051327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1129349\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":46,"alternative-id":["10.3389\/fcvm.2023.1129349"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1129349","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,21]]},"article-number":"1129349"}}